Development of New Monoclonal Antibodies Recognizing Human Prostate-specific Membrane Antigen (PSMA)

Case ID:
C14329
Disclosure Date:
8/14/2016

Unmet Need

Prostate-specific membrane antigen (PSMA, also known as GCPII) is a validated target for prostate cancer imaging and therapy. Macromolecular reagents, most notably monoclonal antibodies (mAbs), offer a viable alternative to small-molecule PSMA ligands for imaging and therapy. However existing anti-PSMA antibodies have several drawbacks, including limited commercial availability, poorly defined epitopes, and lack of data on cross-reactivity towards GCPII paralogs and orthologs.


Technology Overview

The technology includes four novel murine monoclonal antibodies (mAbs) that recognize human PSMA. One of these novel mAbs, 5D3, has approximately 10-fold higher affinity for PSMA than the clinically validated mAb J591 and therefore is a prime candidate for the development of next-generation theranostic agents targeting PSMA.


Stage of Development 

mAbs characterized by western-blot, ELISA, IHC, immunocytochemistry, flow cytometry, immunofluorescence and in a cell-based model. Data from a mouse xenograft model demonstrate feasibility for in vivo imaging.  


Publications: The Prostate 77:749-764 (2017)

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
DEVELOPMENT OF NEW MONOCLONAL ANTIBODIES RECOGNIZING HUMAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) PCT: Patent Cooperation Treaty United States 16/475,805 11,773,182 7/3/2019 10/3/2023 6/16/2039 Granted
DEVELOPMENT OF NEW MONOCLONAL ANTIBODIES RECOGNIZING HUMAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) CON: Continuation United States 18/478,239   9/29/2023     Pending
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Jeanine Pennington
jpennin5@jhmi.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum